 |
|
|
| |
Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients:
An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies
|
| |
| |
Reported by Jules Levin
ID Week 2016 Oct 26-30 New Orleans
R Nahass1, E Lawitz2, I Jacobson3, P Kwo4, M Nguyen5, JC Yang6, LM Stamm6, S Lu6, H Dvory-Sobol6, S Naik6, J Llewellyn6, DM Brainard6, JG McHutchison6, M Curry7, K Kowdley8, N Reau9, EJ Gane10
1ID Care, Hillsborough, New Jersey; 2Texas Liver Institute, San Antonio, Texas; 3Mount Sinai Beth Israel, New York, New York; 4Indiana University School of Medicine, Indianapolis, Indiana; 5Stanford University, Stanford, California; 6Gilead Sciences, Inc., Foster City, California; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts; 8Swedish Medical Center, Seattle, Washington; 9Rush University Medical Center, Chicago, Illinois; 10Auckland Clinical Studies Ltd, Auckland, New Zealand
|
| |
|
|
|
|
|
